Bevacizumab 5 or 7.5 mg/kg in metastatic XXXX can be infused safely over 10 minutes.

@entity5 @entity1 @entity56 @entity14
BACKGROUND: Bevacizumab is a humanized monoclonal antibody that blocks vascular endothelial factor. It demonstrated an efficacy in many @entity5 types. The standard recommendation of administration is the 90-, 60-, and 30-min infusion sequence for all doses. We evaluated in this study the possibility of reducing infusion time to 10 min for bevacizumab given at 5 or 7.5 mg/kg in metastatic @entity14 (MCRC). @entity1 AND METHODS: All @entity1 who received bevacizumab for MCRC were analyzed. @entity1 were divided into two groups: Group A (bevacizumab was given in the 90-, 60-, and 30-min infusion sequence) and group B (bevacizumab was given over 10 min). @entity1 ' medical records were used to identify any @entity56 ( @entity56 ) possibly related to bevacizumab. RESULTS: There were 38 @entity1 in group A and 43 in group B. In group A, 459 doses of bevacizumab were given (286 doses at 5 mg/kg and 173 doses at 7.5 mg/kg). No @entity56 occurred in this group. In group B, 527 doses of bevacizumab were given (335 doses at 5 mg/kg and 192 doses at 7.5 mg/kg). Only two events of @entity56 grade 2 were reported in the 7.5 mg/kg infusions. Both of them were easily resolved with symptomatic treatment. CONCLUSIONS: Bevacizumab 5 or 7.5 mg/kg in MCRC can be infused safely over 10 min.
